X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (48) 48
index medicus (42) 42
male (39) 39
middle aged (38) 38
female (37) 37
adult (33) 33
hematology (32) 32
aged (28) 28
transplantation (24) 24
retrospective studies (19) 19
treatment outcome (19) 19
life sciences (17) 17
chemotherapy (15) 15
cancer (14) 14
immunology (14) 14
adolescent (13) 13
oncology (13) 13
analysis (12) 12
prognosis (12) 12
young adult (12) 12
bone-marrow-transplantation (11) 11
hematology, oncology and palliative medicine (11) 11
stem cells (10) 10
[sdv.can]life sciences [q-bio]/cancer (9) 9
lymphomas (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
care and treatment (8) 8
disease-free survival (8) 8
lymphoma (8) 8
research (8) 8
survival analysis (8) 8
transplantation, autologous (8) 8
versus-host-disease (8) 8
combined modality therapy (7) 7
diagnosis (7) 7
fluorodeoxyglucose f18 (7) 7
high-dose therapy (7) 7
multiple myeloma (7) 7
positron-emission tomography (7) 7
risk factors (7) 7
stem cell transplantation (7) 7
survival rate (7) 7
tomography, x-ray computed (7) 7
transplantation, homologous (7) 7
[ sdv.can ] life sciences [q-bio]/cancer (6) 6
disease (6) 6
hematopoietic stem cell transplantation (6) 6
hematopoietic stem cell transplantation - methods (6) 6
hodgkin disease - drug therapy (6) 6
hodgkin disease - pathology (6) 6
leukemia (6) 6
positron-emission-tomography (6) 6
transplantation conditioning - methods (6) 6
hodgkin lymphoma (5) 5
hodgkin's disease (5) 5
mantle cell lymphoma (5) 5
mortality (5) 5
neoplasm staging (5) 5
neutropenia (5) 5
patient outcomes (5) 5
prospective studies (5) 5
relapse (5) 5
remission induction (5) 5
salvage therapy (5) 5
stem-cell transplantation (5) 5
survival (5) 5
trial (5) 5
abridged index medicus (4) 4
abvd (4) 4
aged, 80 and over (4) 4
allogeneic stem cell transplantation (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
autografts (4) 4
blood (4) 4
child (4) 4
criteria (4) 4
cytarabine (4) 4
dexamethasone (4) 4
health aspects (4) 4
hemic and lymphatic diseases (4) 4
hodgkin disease (4) 4
hodgkin disease - diagnosis (4) 4
hodgkin disease - therapy (4) 4
infection (4) 4
lymphoma, non-hodgkin - therapy (4) 4
management (4) 4
medical research (4) 4
medicine & public health (4) 4
mesh : female (4) 4
mesh : humans (4) 4
mesh : male (4) 4
mesh : middle aged (4) 4
multivariate analysis (4) 4
patients (4) 4
pet imaging (4) 4
radiotherapy (4) 4
reduced-intensity conditioning (4) 4
sensitivity and specificity (4) 4
studies (4) 4
usage (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Microbial Ecology, ISSN 0095-3628, 4/2014, Volume 67, Issue 3, pp. 690 - 699
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2017, Volume 377, Issue 13, pp. 1250 - 1260
Journal Article
JAMA, ISSN 0098-7484, 12/2017, Volume 318, Issue 21, pp. 2099 - 2110
Journal Article
Journal Article
Journal Article
Annals of Hematology, ISSN 0939-5555, 6/2019, Volume 98, Issue 6, pp. 1435 - 1440
The anti-CD38 monoclonal antibody daratumumab is approved as a single agent for the treatment of patients with relapsed and refractory multiple myeloma (RRMM)... 
Real life | Oncology | Medicine & Public Health | Hematology | Daratumumab | Multiple myeloma | CRITERIA | DEXAMETHASONE | MONOTHERAPY | HEMATOLOGY | Cytogenetics | Development and progression | Relapse | Analysis | Diseases
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4158 - 4158
Abstract Background. Mantle Cell Lymphoma (MCL) drug resistance are highly dependent on B-cell-receptor signaling, Bcl-2 and the microenvironment. Ibrutinib... 
Journal Article
American Journal of Hematology, ISSN 0361-8609, 06/2018, Volume 93, Issue 6, pp. 729 - 735
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 1530 - 1530
Background. Novel targeted therapies have demonstrated high efficacy in relapse and/or refractory (R/R) MCL. Ibrutinib, a first in class BTK inhibitor, is... 
Journal Article